Abstract
Pharmacometric models are a powerful tool and an essential aspect of modern pharmaceutical research, drug development and clinical practice. They provide a quantitative framework for understanding the complex interaction between drug characteristics, patients, and diseases, enabling the selection of drugs and dosing regimens to optimize therapeutic outcomes (1). Patients vary in their response to medications due to genetic, physiological, clinical, or environmental factors. Different responses to therapy can be of pharmacokinetic, pharmacodynamic, or disease-related nature, indicating that one dose does not fit all patients. Addressing the variability is essential for stratifying dosing regimens for specific patient populations. One of the key advantages of pharmacometric models lies in their ability to distinguish different levels of variability in drug behavior, especially in quantifying and mathematically describing the sources of interindividual variability, as well as predicting how different patients will react to the drug. This knowledge is invaluable for specific patient populations to identify optimal dosing regimens that provide maximum efficacy with minimal side effects. Model-informed dosing is significant in pediatrics, elderly, critically ill patients, or patients with impaired liver/kidney function, where a one-size-fits-all dosing recommendation is often not applicable (2). The lecture will present research results where pharmacometric models contribute to new insights and improve drug development by unlocking the potential of personalized medicine.
References
1. Roganović M, Homšek A, Jovanović M, Topić Vučenović V, Ćulafić M, Miljković B, Vučićević, K. Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice. Arh farm 2021; 71: 336-53.
2. Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, Reny JL, Daali Y, Eiermann B, Cook J, Lesko L, McLachlan AJ, Rostami-Hodjegan A. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol 2021; 61: 225-45.
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).